Asia
The AP report shows that in China, Mundipharma representatives are informing doctors that OxyContin is less addictive than other painkillers, which is a similar tactic the company used in the 1990s in the United States.
Mayo Clinic and Hitachi, Ltd. have reached an agreement in principle to build a carbon ion treatment facility as part of Mayo Clinic’s recently announced integrated oncology facility which will be constructed at Mayo Clinic’s campus in Jacksonville, Florida.
Eisai Co., Ltd. announced that it has launched the Equfina 50mg TABLETS for the indication of improvement of the wearing-off phenomenon in patients with Parkinson’s disease under treatment with a drug containing levodopa in Japan.
Companies from across the globe provide updates on their businesses and pipelines.
Have you ever given it a thought that one day we will witness lab grown organs? Well, if you haven’t then this article will make you think about the future of sciences.
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever
The Dubai Government Workshop, in collaboration with the Emirates Specialty Hospital, celebrated the World Diabetes Day, which falls on November 14 of every year, to help increase public awareness on treatment methods for diabetes and other chronic diseases.
Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
ZEISS and Kyoto University are intensifying their cooperation and have signed a new strategic research agreement.
Global BioLife Inc, the U.S. subsidiary of Singapore eDevelopment Ltd, will present its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the ASM Biothreats Conference, 28 to 30 January, 2020 in Arlington, Virginia.
PRESS RELEASES